Vor Biopharma Stock Performance
| VOR Stock | USD 13.00 0.99 7.08% |
The entity has a beta of -0.69, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Vor Biopharma are expected to decrease at a much lower rate. During the bear market, Vor Biopharma is likely to outperform the market. At this point, Vor Biopharma has a negative expected return of -0.26%. Please make sure to validate Vor Biopharma's value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Vor Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Vor Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (7.08) | Five Day Return (20.92) | Year To Date Return 11.68 | Ten Year Return (98.27) | All Time Return (98.27) |
Last Split Factor 1:20 | Last Split Date 2025-09-19 |
1 | Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 11/13/2025 |
2 | Disposition of 33842 shares by Reprogrammed Interchange Llc of Vor Biopharma at 31.9181 subject to Rule 16b-3 | 11/14/2025 |
3 | Disposition of 4164831 shares by Kress Jean-paul of Vor Biopharma at 17.8 subject to Rule 16b-3 | 12/05/2025 |
4 | Vor Biopharma Stock Explodes 40 percent as JPMorgan Sees Massive Upside Ahead | 12/09/2025 |
5 | Vor Biopharma Is Up 45.6 percent After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed - Yahoo Finance | 12/12/2025 |
6 | Vor Bio Announces 150 Million Private Placement | 12/15/2025 |
7 | Insider Trading | 12/18/2025 |
8 | Vor Bio Appoints RA Capitals Andrew Levin, M.D., Ph.D., and Forbions Wouter Joustra to Board of Directors | 12/23/2025 |
9 | Vor Biopharma Inc. Receives Average Rating of Moderate Buy from Analysts - MarketBeat | 12/26/2025 |
10 | Portfolio Update How Vor Biopharma Inc. stock benefits from global expansion - Trade Risk Report Fast Entry and Exit Trade Plans - moha.gov.vn | 01/02/2026 |
11 | Vor Biopharma Receives New Buy Rating From Citigroup V - GuruFocus | 01/09/2026 |
12 | Vor Biopharma Inc. Receives Consensus Rating of Moderate Buy from Brokerages - MarketBeat | 01/21/2026 |
13 | Citi Maintains Vor Biopharma With Buy Rating, Maintains Target Price 50 - | 01/30/2026 |
| Begin Period Cash Flow | 33.8 M | |
| Total Cashflows From Investing Activities | 96.9 M |
Vor Biopharma Relative Risk vs. Return Landscape
If you would invest 2,241 in Vor Biopharma on November 3, 2025 and sell it today you would lose (941.00) from holding Vor Biopharma or give up 41.99% of portfolio value over 90 days. Vor Biopharma is generating negative expected returns assuming volatility of 10.487% on return distribution over 90 days investment horizon. In other words, 94% of stocks are less volatile than Vor, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Vor Biopharma Target Price Odds to finish over Current Price
The tendency of Vor Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 13.00 | 90 days | 13.00 | about 56.06 |
Based on a normal probability distribution, the odds of Vor Biopharma to move above the current price in 90 days from now is about 56.06 (This Vor Biopharma probability density function shows the probability of Vor Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon Vor Biopharma has a beta of -0.69. This entails as returns on the benchmark increase, returns on holding Vor Biopharma are expected to decrease at a much lower rate. During a bear market, however, Vor Biopharma is likely to outperform the market. Additionally Vor Biopharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Vor Biopharma Price Density |
| Price |
Predictive Modules for Vor Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vor Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Vor Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Vor Biopharma is not an exception. The market had few large corrections towards the Vor Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vor Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vor Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.57 | |
β | Beta against Dow Jones | -0.69 | |
σ | Overall volatility | 5.05 | |
Ir | Information ratio | -0.06 |
Vor Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vor Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vor Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Vor Biopharma generated a negative expected return over the last 90 days | |
| Vor Biopharma has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (116.91 M) with profit before taxes, overhead, and interest of 0. | |
| Vor Biopharma has about 151.09 M in cash with (99.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97. | |
| Latest headline from simplywall.st: Nkarta Insiders Make Handsome Sum Selling Stock At US2.06 Per Share |
Vor Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vor Stock often depends not only on the future outlook of the current and potential Vor Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vor Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.4 M | |
| Cash And Short Term Investments | 91.9 M |
Vor Biopharma Fundamentals Growth
Vor Stock prices reflect investors' perceptions of the future prospects and financial health of Vor Biopharma, and Vor Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vor Stock performance.
| Return On Equity | -1.25 | ||||
| Return On Asset | -1.44 | ||||
| Current Valuation | 374.29 M | ||||
| Shares Outstanding | 41.52 M | ||||
| Price To Book | 3.14 X | ||||
| EBITDA | (117.66 M) | ||||
| Net Income | (116.91 M) | ||||
| Cash And Equivalents | 151.09 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 31.83 M | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 12.95 X | ||||
| Book Value Per Share | (246.54) X | ||||
| Cash Flow From Operations | (99.66 M) | ||||
| Earnings Per Share | (386.86) X | ||||
| Market Capitalization | 539.76 M | ||||
| Total Asset | 142.89 M | ||||
| Retained Earnings | (456.99 M) | ||||
| Working Capital | 77.89 M | ||||
About Vor Biopharma Performance
Assessing Vor Biopharma's fundamental ratios provides investors with valuable insights into Vor Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vor Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.74) | (0.77) | |
| Return On Capital Employed | (1.12) | (1.18) | |
| Return On Assets | (0.74) | (0.77) | |
| Return On Equity | (1.39) | (1.32) |
Things to note about Vor Biopharma performance evaluation
Checking the ongoing alerts about Vor Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vor Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vor Biopharma generated a negative expected return over the last 90 days | |
| Vor Biopharma has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (116.91 M) with profit before taxes, overhead, and interest of 0. | |
| Vor Biopharma has about 151.09 M in cash with (99.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97. | |
| Latest headline from simplywall.st: Nkarta Insiders Make Handsome Sum Selling Stock At US2.06 Per Share |
- Analyzing Vor Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vor Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Vor Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vor Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vor Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vor Biopharma's stock. These opinions can provide insight into Vor Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.